Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Techne (TECH)

Bio-Techne Q4 revenue rises 4% to $317.0 million; GAAP EPS is a loss

Mixed Impact 3 of 5 earnings Written later

Bio-Techne reported fourth-quarter fiscal 2025 net sales up 4% to $317.0 million and adjusted EPS of $0.53, versus $0.49 a year earlier. GAAP EPS was a loss of $0.11, compared with $0.25, after an $83.1 million impairment tied to the planned divestiture of its Exosome Diagnostics business. The company also declared a quarterly dividend of $0.08 per share.

Key points

  • Q4 net sales $317.0 million, up 4% reported and 3% organic; full-year net sales $1.2 billion, up 5%
  • Q4 GAAP EPS was ($0.11) versus $0.25; full-year GAAP EPS was $0.46 versus $1.05
  • Q4 adjusted EPS $0.53 versus $0.49; full-year adjusted EPS $1.92 versus $1.77
  • Exosome Diagnostics impairment of $83.1 million in the quarter; dividend of $0.08 per share payable August 29, 2025 to holders of record August 18, 2025

The filing

CompanyBio-Techne (TECH)
Form8-K, current report
Filed with the SECAug 6, 2025, 6:30 AM ET
Accession number0001558370-25-010393

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.